What Menopause Actually Does, and What Helps

Menopause is usually described as a list. Hot flashes, disturbed sleep, mood changes, dryness. Presented that way, it sounds like an inconvenient season to be endured quietly until it passes.

The physiology tells a different story. Oestrogen receptors are distributed throughout the body, in bone, brain, blood vessels, urogenital tissue, and skin. When oestrogen declines, every one of those tissues registers the change.

That is why symptoms which seem unrelated often are not. It also explains why the question of treatment matters more than the conversation around it usually allows.

This guide covers what the transition does across the body. It examines the research that shaped a generation of medical advice, and what the current evidence supports. It is longer than most of our guides because the subject deserves it.

What Menopause Does Across the Body

The clinical definition is simple. The physiological consequences reach considerably further than most descriptions suggest.

The definition, and the transition before it

Menopause itself is defined by a single marker: twelve consecutive months without menstruation. It typically occurs around the age of 51, though the range is wide and entirely normal at either end.

The years preceding it matter more than the date does. Perimenopause involves fluctuating rather than simply declining hormones. Symptoms during this phase are therefore unpredictable and hard to attribute.

Vasomotor symptoms, and how long they last

Hot flashes and night sweats are the symptoms most associated with menopause, and they are genuinely common. Data from the SWAN study found up to 80 percent of women experience them.

The duration is the part rarely mentioned. Median duration in that research was 7.4 years, and for some women symptoms persist considerably longer. Describing this as a brief phase misrepresents what many people actually experience.

Bone, and why it matters urgently

Oestrogen restrains the cells that break down bone. When it declines, that restraint lifts and bone loss accelerates sharply during the years around the transition.

This process is silent until a fracture occurs, which is precisely what makes it serious. Bone density lost during this window is difficult to recover, so prevention carries far more weight than correction.

Cardiovascular and metabolic change

Oestrogen influences blood vessel function and lipid profiles. Its decline is associated with shifts in cholesterol, blood pressure, and fat distribution toward the abdomen.

Insulin sensitivity changes too. A 2024 Menopause Society meta-analysis of 17 randomised trials examined this directly. It found hormone therapy reduced insulin resistance and prediabetes incidence.

The genitourinary syndrome, which nobody discusses

Urogenital tissue is densely populated with oestrogen receptors. Declining levels produce dryness, discomfort, urinary urgency, and increased susceptibility to infection.

Unlike hot flashes, this cluster does not resolve on its own and tends to progress without treatment. It is also among the most treatable, which makes the silence around it particularly unfortunate.

The Study That Changed Everything, and What It Actually Found

Understanding this history is necessary, because it still shapes what women are told today.

What the Women’s Health Initiative was

The Women’s Health Initiative launched in 1991 as a major federally funded research programme. It enrolled more than 160,000 participants across randomised trials and an observational study.

Part of it tested whether hormone therapy prevented chronic disease. At the time, hormone therapy was widely prescribed for symptoms and for presumed cardiovascular protection. Those assumptions had never been rigorously tested.

When results were announced in 2002, prescribing collapsed almost overnight. Use fell dramatically across multiple countries and has never fully recovered.

The detail that changes the interpretation

Here is what the headlines omitted. The trial tested one formulation, conjugated equine oestrogen with medroxyprogesterone acetate. The average participant age was 63.

That matters enormously. Most women seeking treatment for menopausal symptoms are considerably closer to the transition itself. The trial population was, on average, more than a decade past it.

Findings from that single formulation then generated class-wide warnings. Those applied to every hormone preparation and every patient group. A result about one drug in one population became a warning about all of them.

The timing hypothesis

Subsequent reanalysis revealed a consistent pattern the original reporting obscured. Outcomes differed sharply depending on when therapy began relative to menopause.

Researchers named this the timing hypothesis, sometimes called the window of opportunity. Initiation before age 60, or within ten years of menopause, showed one profile. Initiation later showed quite another.

A narrative review in 2026 summarised the position plainly. Cardiovascular outcomes vary considerably according to formulation, route of administration, timing, and individual factors. None of that nuance survived the 2002 coverage.

What the Current Evidence Supports

Professional society guidance has moved substantially. Here is where it currently stands.

Hormone therapy for symptoms

The 2022 position statement from The Menopause Society is direct. Hormone therapy is the most effective treatment available for vasomotor symptoms and for genitourinary syndrome of menopause.

It has also been shown to prevent bone loss and fracture. The United Kingdom’s NICE guidance, reviewed in late 2024, reaches broadly similar conclusions about symptom management.

Route of administration changes the risk

This distinction is clinically significant and rarely explained. Oral formulations carry an increased risk of venous thromboembolism, meaning blood clots.

Transdermal preparations behave differently. A 2026 review notes that transdermal estradiol with micronised progesterone does not appear to increase that risk. It bypasses first-pass liver metabolism.

Transdermal delivery also appears particularly favourable for women with existing metabolic risk factors. Anyone weighing this decision should ask specifically about route rather than treating hormone therapy as a single choice.

Where the guidance still holds firm

Balance requires stating this clearly. Major medical societies do not recommend hormone therapy for preventing chronic disease. The United States Preventive Services Task Force reaffirmed that position in 2022.

The distinction is between treating symptoms and preventing future illness. Evidence supports the first far more strongly than the second. Reading the reappraisal as a blanket endorsement would be a mistake.

A genuine caution from recent practice

Honesty requires including this alongside the rest. A review in Clinical Endocrinology tracked what followed rising prescriptions. Unscheduled bleeding on hormone therapy rose roughly 43 percent in the United Kingdom between 2021 and 2024.

Referrals for suspected cancer rose correspondingly, and endometrial cancer diagnoses increased by 2 percent over the same period. The review observes that women accessing therapy in practice differ from trial participants, often carrying more coexisting conditions.

None of that argues against treatment. It argues for proper monitoring. Report any unexpected bleeding promptly rather than assuming it is part of the process.

Non-Hormonal Options That Genuinely Work

Hormone therapy is not suitable or desirable for everyone, and the alternatives have improved considerably.

A genuinely new class of medication

Fezolinetant represents the first meaningful non-hormonal advance in this area for some time. It works by blocking neurokinin 3 receptors in the brain region governing temperature regulation.

The trial data is strong. A phase 2b study enrolled 352 participants. Between 81 and 95 percent achieved at least a halving of symptoms. Placebo managed 58.5 percent.

An earlier proof of concept study found symptom frequency fell roughly 88 to 93 percent from baseline. Placebo produced 38 to 46 percent. Effects appeared within the first week of treatment.

Other prescription routes

Certain antidepressants have established evidence for reducing vasomotor symptoms, at doses lower than those used for mood. Other medications originally developed for different purposes also feature in current guidance.

Local vaginal oestrogen deserves separate mention. Absorption into the bloodstream is minimal, so it often suits women who cannot use systemic therapy. It treats the urogenital symptoms that otherwise progress.

The treatment gap

One figure captures the scale of the problem. A retrospective study reviewed records of 1,016 women presenting with menopausal symptoms, the overwhelming majority reporting hot flashes.

Nearly 40 percent had no documentation of any prescription therapy being offered. Thirteen percent had no therapy of any kind recorded, including non-prescription options and lifestyle advice.

Those women attended appointments and described their symptoms. The system then offered them nothing at all.

What Menopause Does to Skin and Hair

This receives far less attention than vasomotor symptoms, despite affecting quality of life considerably.

The collagen figure, and what it means

Skin functions as an endocrine organ and responds directly to oestrogen. Research published in Climacteric reports a collagen reduction of approximately 30 percent across the first five years following menopause.

A further decline of roughly 2 percent annually follows for the next fifteen years. Crucially, that loss correlates more closely with duration of oestrogen deficiency than with chronological age.

This explains something many women describe and are rarely believed about. Skin can change noticeably within a relatively short period, and the perception of a sudden shift is not imagined.

What hormone therapy does to skin, honestly

Oestrogen replacement has been shown to increase epidermal thickness and skin collagen content. One study recorded a 6.49 percent increase in skin collagen following six months of oral oestrogen.

Effect sizes are modest, though, and largely apply to therapy begun in the early post-menopausal window. The honest framing is that it slows loss and partially restores thickness. It does not return skin to its previous state.

Skin benefit alone is not a reason to begin hormone therapy, and no guideline suggests otherwise. It is better understood as a welcome effect for women taking it for other reasons.

Topical care that remains worthwhile

Retinoids and daily sun protection retain their strong evidence regardless of hormonal status. Barrier support becomes more important as skin thins and dryness increases.

The Belldiva skin barrier repair guide covers what supports that layer. Our hormone skincare routine guide addresses the adjustments worth making.

What Else Genuinely Helps

These carry real evidence, and one of them addresses several systems at once.

On the supplement aisle

The market for menopause supplements is enormous and the evidence behind most of it is thin. Black cohosh, evening primrose, and various botanical blends have been studied repeatedly with inconsistent results.

That does not make them harmful, and some women report benefit. It does mean the packaging claims exceed what the trials support. Spending there while effective prescription options go unoffered is a poor trade.

Common Questions About Menopause

Direct answers to what comes up most, with the caveat that individual decisions belong with your doctor.

Questions about hormone therapy

Questions about timing and alternatives

Sources and research references

Belldiva’s Curated Beauty and Wellness Brands